Prognostic and clinicopathological significance of FGFR1 gene amplification in resected esophageal squamous cell carcinoma: a meta-analysis

Yan Wang, Yanming Wu, Jialong Li, Yutian Lai, Kun Zhou, Guowei Che


Background: Previous studies about the prognostic and clinicopathological significance of fibroblast growth factor receptor 1 (FGFR1) amplification in resected esophageal squamous cell carcinoma (ESCC) are controversial. Therefore, the aim of the current meta-analysis was to determine the association of FGFR1 amplification with prognosis and clinicopathological characteristics of resected ESCC patients.
Methods: The PubMed, EMBASE, Web of Science, The Cochrane Library, CNKI, Wanfang, VIP and SinoMed databases were searched systematically from the establishment date of databases to April 1, 2019 to identify related studies. The correlations of FGFR1 amplification of prognosis and clinicopathological characteristics in ESCC were assessed by the combined hazard ratio (HR) with 95% confidence interval (CI) and combined odds ratio (OR) with 95% CI, respectively. All statistical analyses were performed by the Stata 12.0 software.
Results: A total of nine retrospective studies involving 2,326 patients who received the surgery were included into the current meta-analysis. The results indicated that FGFR1 amplification was significantly correlated with worse overall survival (OS) (HR =1.50, 95% CI: 1.25–1.81, P<0.001), disease-free survival (DFS) (HR =1.58, 95% CI: 1.27–1.96, P<0.001), lymph node metastasis (OR =1.45, 95% CI: 1.13–1.86, P=0.004), higher TNM stage (OR =1.33, 95% CI: 1.03–1.72, P=0.027) and poorer differentiation (OR =1.10, 95% CI: 1.07–1.13, P<0.001).
Conclusions: The current meta-analysis strongly demonstrates that FGFR1 amplification is an independent prognostic risk factor for resected ESCC patients and more prevalent among patients with advanced tumor stage and poorer differentiation.